This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Legend Biotech (LEGN) Up 12% on Reports of Takeover Bid
by Zacks Equity Research
A third-party article suggests that Legend Biotech (LEGN) hired investment banking firm Centerview Partners to help its board review the takeover offer.
Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion
by Zacks Equity Research
Bristol Myers Squibb (BMY) obtains FDA approval for the label expansion of CAR T cell therapy Breyanzi to treat adult patients with relapsed or refractory follicular lymphoma.
2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
2seventy bio, Inc. (TSVT) delivered earnings and revenue surprises of -12.50% and 4.23%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On CRISPR Therapeutics' (CRSP) first-quarter 2024 earnings call, investors' focus is likely to be on the updates related to the first sales numbers of its newly approved gene therapy, Casgevy.
Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
by Zacks Equity Research
Regeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
2seventy bio, Inc. (TSVT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why
by Zacks Equity Research
The FDA's recent nod to 2seventy bio's (TSVT) Abecma in earlier lines of treatment for relapsed/refractory multiple myeloma is a positive. Also, the R&D asset divestiture to Regeneron is saving costs.
The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
by Zacks Equity Research
Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals are part of the Zacks top Analyst Blog.
Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Abecma
by Zacks Equity Research
Bristol Myers (BMY) wins FDA approval for CAR T cell immunotherapy, Abecma, in earlier lines of treatment for patients with relapsed or refractory multiple myeloma.
FDA Expands J&J's (JNJ) Carvykti Label in Multiple Myeloma
by Zacks Equity Research
Following the label expansion, J&J's (JNJ) Carvykti is approved as a second-line treatment for adults with relapsed/refractory myeloma. It was initially approved for use as a fifth- or later-line treatment.
Bristol Myers (BMY) Gets EC Nod for Abecma's Label Expansion
by Zacks Equity Research
Bristol Myers (BMY) wins European Commission's approval for the label expansion of its CAR T cell immunotherapy Abecma in earlier lines for triple-class exposed relapsed and refractory multiple myeloma.
Bristol Myers' (BMY) Abecma Gets ODAC Votes for Label Expansion
by Zacks Equity Research
Bristol Myers' (BMY) Abecma gets eight out of 11 votes from the FDA's ODAC for patients with triple-class exposed relapsed or refractory multiple myeloma in earlier lines of therapy.
Should You Buy 2seventy bio (TSVT) Ahead of Earnings?
by Zacks Equity Research
2seventy bio (TSVT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Bristol Myers (BMY), TSVT CAR T-Cell Therapy to Face FDA's ODAC
by Zacks Equity Research
Bristol Myers (BMY) and its partner TSVT announce that the FDA's ODAC will meet in March to review data supporting the label expansion for CAR T-cell therapy.
Biotech Stock Roundup: GSK's Q4 Results, VRTX Gains on Update, TSVT Up on REGN Deal
by Zacks Equity Research
Earnings from GSK and other updates from 2seventy bio (TSVT) were in focus in the biotech sector.
2seventy bio, Inc. (TSVT) Surges 28.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
2seventy bio, Inc. (TSVT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
2seventy bio (TSVT) Divests R&D Assets to Regeneron, Stock Up
by Zacks Equity Research
2seventy bio (TSVT) inks an asset purchase agreement with Regeneron to sell its oncology and autoimmune pipeline to the latter.
All You Need to Know About 2seventy bio, Inc. (TSVT) Rating Upgrade to Strong Buy
by Zacks Equity Research
2seventy bio, Inc. (TSVT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
by Sanghamitra Saha
Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include DouYu International (DOYU), Regis (RGS), 2seventy bio Inc. (TSVT), atai Life Sciences (ATAI) and GameStop (GME).
Bristol Myers (BMY) Stops Late-Stage Colorectal Cancer Study
by Zacks Equity Research
Bristol Myers (BMY) decides to discontinue the phase III colorectal cancer study as it was unlikely to meet its primary endpoints upon completion.
Bristol Myers (BMY) Partners With SystImmune for Oncology Drug
by Zacks Equity Research
Bristol Myers (BMY) is set to co-develop and co-commercialize oncology candidate BL-B01D1 in the United States with SystImmune.
Biotech Stock Roundup: BMY, TSVT Down on Setback, TRDA, MOR Offer Updates
by Zacks Equity Research
Regulatory setback for Bristol Myers (BMY) and other updates are in focus in the biotech sector.
Bristol Myers (BMY), TSVT Cell Therapy Abecma Faces Setback
by Zacks Equity Research
Bristol Myers Squibb (BMY) and 2seventy bio, Inc.'s efforts to seek approval for the label expansion of Abecma for earlier lines of treatment face a roadblock.
2seventy bio, Inc. (TSVT) Loses -44.63% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
2seventy bio, Inc. (TSVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.